Although Anaphore Inc. has yet to enter the clinic with a program from its protein therapeutics platform, the company jumped at the opportunity to add a second biologics technology and thinks last month's stock acquisition of RuiYi Inc. will allow it to accomplish the difficult task of targeting GPCRs with mAbs.

Anaphore's TrimerX technology is based on tetranectin, a protein that contains five loops on each of its three plasminogen binding domains. By altering the amino acid sequence of the loops, the company can generate trivalent protein therapeutic analogs, dubbed Atrimers, which can bind a variety of targets (see BioCentury, Jan. 29, 2009).